<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137253</url>
  </required_header>
  <id_info>
    <org_study_id>091489</org_study_id>
    <nct_id>NCT01137253</nct_id>
  </id_info>
  <brief_title>Autonomic Nervous System and Nitric Oxide Interactions</brief_title>
  <official_title>The Autonomic Nervous System, Nitric Oxide and TPA Interactions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are interested in the role of the autonomic nervous system in the
      regulation of endothelial function among obese hypertensive subjects. In particular, the
      investigators will study how endothelial function (response to intra-arterial acetylcholine)
      changes during autonomic withdrawal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>2 hours</time_frame>
    <description>The dose response curve to intrabrachial vasodilators will be determined using the peak forearm blood flow during the last 5 minutes of each drug infusion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Trimethaphan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Response to intrabrachial vasodilators during autonomic withdrawal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Response to intrabrachial vasodilators during saline intravenous (IV) infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethaphan</intervention_name>
    <description>Trimethaphan 4 mg/min IV, for the duration of the study (approximately 2 hours)</description>
    <arm_group_label>Trimethaphan</arm_group_label>
    <other_name>Blocked</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Response to intrabrachial vasodilators during IV saline infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Intact</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For lean healthy volunteers:

          -  20 subjects (10 males and 10 females) aged 18-60 yr.

          -  All potential volunteers will have routine blood test to screen for hepatic, renal,
             and hematological abnormalities.

          -  Body mass index &lt; 25Kg/m2 .

          -  Female volunteers of childbearing potential will undergo HCG pregnancy test at
             screening and again on the study day.

        For Obese subjects with high blood pressure.

          -  20 subjects (10 males and 10 females) aged 18-60 yr.

          -  All potential volunteers will have routine blood test to screen for hepatic, renal,
             and hematological abnormalities.

          -  Body mass index &gt; 30 and less than 40 Kg/m2

             *High blood pressure (systolic=130 and diastolic = 85 mmHg)

          -  Female volunteers of childbearing potential will undergo serum HCG pregnancy test at
             screening and urine HCG pregnancy test again on the study day.

        Exclusion criteria:

          -  Pregnant females

          -  Subjects unable to give voluntary informed consent

          -  Subjects on anticoagulant drugs or anemic

          -  Subjects with a recent medical illness

          -  Subjects with a history of coronary heart disease

          -  Subjects with known kidney or liver disease

          -  Subjects with recent weight loss or consuming low carbohydrate diet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2010</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Alfredo Gamboa</investigator_full_name>
    <investigator_title>Research Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Nitric Oxide</keyword>
  <keyword>Autonomic Nervous System</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Trimethaphan</mesh_term>
    <mesh_term>Trimethaphan camsylate</mesh_term>
    <mesh_term>Vasodilator Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

